GleamWall
中文EN

MTVA MetaVia Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1638287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.2%
TTM EPS YoY93.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-359.0%
ROA-129.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.59M$3.48M$2.10M$241,000$1.91M$2.32M$2.33M$4.06M
SG&A expense$2.10M$1.91M$1.92M$1.80M$1.56M$1.98M$1.56M$1.53M
Operating income-$4.69M-$5.38M-$4.03M-$2.05M-$3.48M-$4.30M-$3.89M-$5.58M
Pretax income-$4.62M-$5.32M-$3.82M-$1.93M-$3.38M-$4.00M-$3.67M-$5.17M
Income tax$0$0$0$0$0$0$0$0
Net income-$4.62M-$5.32M-$3.82M-$1.93M-$3.38M-$4.00M-$3.67M-$5.17M
EBITDA-$4.69M-$5.38M-$4.02M-$2.04M-$3.47M-$4.30M-$3.88M-$5.58M
EPS (basic)-0.69-0.90-0.79—-1.52-2.87-3.93—
EPS (diluted)-0.69-0.90-0.79—-1.52-2.87-3.93—
Weighted avg. shares (diluted)6.68M5.93M4.86M—2.22M1.39M933,109—
Banking
Net interest income$72,000$73,000$85,000$85,000$151,000$146,000$128,000$209,000
Balance sheet
Cash & equivalents$8.78M$12.63M$13.73M$10.28M$14.28M$17.59M$11.19M$16.02M
Current assets$9.35M$13.07M$14.16M$10.88M$14.65M$18.32M$11.96M$16.07M
PP&E, net$22,000$8,000$12,000$17,000$22,000$27,000$30,000$34,000
Total assets$9.55M$13.27M$14.39M$11.12M$14.77M$18.46M$12.13M$16.26M
Current liabilities$7.06M$6.35M$5.19M$5.65M$8.43M$8.82M$7.71M$8.27M
Total liabilities$7.14M$6.45M$5.32M$5.79M$8.43M$8.84M$7.75M$8.33M
Shareholders' equity$2.41M$6.82M$9.07M$5.33M$6.33M$9.62M$4.38M$7.93M
Shares outstanding6.74M6.58M5.16M2.31M24.21M24.19M8.65M785,194
Cash flow statement
Operating cash flow-$3.72M-$3.76M-$4.26M-$4.86M-$2.96M-$3.07M-$4.82M-$5.43M
Capital expenditure———$0$0——$0
Free cash flow———-$4.86M-$2.96M——-$5.43M
Investing cash flow———$0$0——$0
Financing cash flow-$117,000$2.67M$7.71M$861,000-$357,000$9.47M-$12,000-$224,000
Depreciation & amortization$7,000$4,000$5,000$5,000$5,000$5,000$4,000$5,000
Stock-based compensation$135,000$130,000$100,000$71,000$97,000$111,000$132,000$160,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.